EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

Blood Cancer Journal

ISSN 2044-5385 · Springer Science and Business Media LLC

Neueste Artikel

  1. Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)

    Melinda SY Tan, Kye Ling Wong, Cinnie Soekojo, Chandramouli Nagarajan, Sarah Burkhill, Xinhua Li, Ho-Jin Shin, Jong Heon Jung, Yeung-Chul Mun, Ho-Young Yhim, Jae Hoon Lee, Ling Cao, Tadao Ishida, Chihiro Shimazaki, Makoto Sasaki, Hiroyuki Takamatsu, Shinsuke Iida, Hirono Iriuchishima, Shuji Ozaki, Karen Tang, Jeffrey Huang, Jerry Teng, Cheng-Shyong Chang, Changki Min, Wenming Chen, Hiroshi Handa, Kihyun Kim, Priti Bahety, Juan Du, Wee Joo Chng

    Erschienen: 2026-11-11DOI: 10.1038/s41408-026-01641-5

  2. Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies

    Ahmed L. Al-Mashhadi, Mikkel R. Simonsen, Elizabeth Smyth, Rose-Marie Amini, Bente Arboe, James R. Cerhan, Iman Chanchiri, Chan Y. Cheah, Jonathan R. Day, Toby A. Eyre, Anne O. Gang, Herve Ghesquieres, Thomas M. Habermann, Eliza Hawkes, Steven Hwang, Ruxandra Irimia, Jennifer B. Jørgensen, Arushi Khurana, Claire Maquet, Matthew Maurer, Lay She Ng, Stephen Opat, Martin B. Pedersen, Christian B. Poulsen, Alexandros Rampotas, Andreea Sima, Karin E. Smedby, Knut B. Smeland, Gita Thanarajasingam, Judith Trotman, Katharine Xing, Simon Østergaard, Diego Villa, Tarec C. El-Galaly

    Erschienen: 2026-11-09DOI: 10.1038/s41408-026-01660-2

  3. Biomarkers of cellular senescence and their association with frailty, clinical outcomes, and survival in multiple myeloma

    Nadine Abdallah, Byron Smith, Thomas A. White, Amanda Heeren, Tanya M. Wildes, Rosalynn Marar, Claire Yee, Anna Bodily, Brian Kotajarvi, Sarah Aug, Francis Buadi, Prashant Kapoor, Angela Dispenzieri, Suzanne Hayman, David Dingli, Wilson Gonsalves, Joselle Cook, Saurabh Zanwar, Moritz Binder, Yi Lin, Taxiarchis Kourelis, Morie A. Gertz, Rahma Warsame, S. Vincent Rajkumar, Jad Sfeir, Nathan K. LeBrasseur, Shaji K. Kumar, Megan M. Weivoda

    Erschienen: 2026-10-30DOI: 10.1038/s41408-026-01652-2

  4. Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-R

    A. Vera de Jonge, Erik van Werkhoven, Marjolein van der Poel, Koen de Heer, Clara P. W. Klerk, Yorick Sandberg, Rozemarijn van Rijn, Rob Fijnheer, Pim Mutsaers, Vibeke K. J. Vergote, Djamila Issa, Aart Beeker, Yavuz M. Bilgin, Lara H. Bohmer, Laurens Nieuwenhuizen, Wendy B. C. Stevens, Roel van Kampen, Rogier Mous, Marc Durian, Tjeerd Snijders, Joost S. P. Vermaat, Otto Visser, Josée M. Zijlstra, Anne I. J. Arens, Ben Zwezerijnen, Danielle van Assema, Bart de Keizer, Henk Hofwegen, Helma Zanders, Brigitta A. G. Schuthof, Robby E. Kibbelaar, Lianne Koens, Liping Fu, Daphne de Jong, David Kurtz, Marcel Nijland, Marie José Kersten, Martine E. D. Chamuleau

    Erschienen: 2026-10-30DOI: 10.1038/s41408-026-01657-x

  5. Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

    Alice X. Wang, Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Carlyn R. Tan, Issam S. Hamadeh, Ross S. Firestone, Eric Jurgens, Kevin Miller, Dhwani Patel, Neha Korde, Alexander M. Lesokhin, Sham Mailankody, Hani Hassoun, Hamza Hashmi, Sridevi Rajeeve, Urvi A. Shah, Kylee Maclachlan, Gunjan L. Shah, Michael Scordo, Heather J. Landau, Sergio A. Giralt, Saad Z. Usmani, Malin Hultcrantz

    Erschienen: 2026-08-07DOI: 10.1038/s41408-026-01594-9

  6. Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia

    Stephen P. Martindale, Roberta Santos Azevedo, Drew A. Harrison, Bethany Tesar, Winnie Nguy, Miranda Stiegler, Valeria Ferre, Vanessa Rai, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Stacey M. Fernandes, John-Hanson Machado, Binu Kandathilparambil Sasi, Aishath Naeem, Christopher J. Ott, Jennifer R. Brown

    Erschienen: 2026-07-13DOI: 10.1038/s41408-026-01559-y

  7. Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients

    Niels W. C. J. van de Donk, Fredrik Schjesvold, Bronno van der Holt, Monique C. Minnema, Ka Lung Wu, Annemiek Broijl, Wilfried W. H. Roeloffzen, Alain Gadisseur, Giuseppe Pietrantuono, Ludek Pour, Vincent H. J. van der Velden, Thomas Lund, Massimo Offidani, Sara Bringhen, Luisa Giaccone, Wida Razawy, Paola Tacchetti, Katia Mancuso, Trine Silkjaer, Jo Caers, Sonja Zweegman, Roman Hájek, Reuben Benjamin, Annette Juul Vangsted, Mario Boccadoro, Francesca Gay, Pieter Sonneveld, Pellegrino Musto

    Erschienen: 2026-06-24DOI: 10.1038/s41408-026-01549-0

  8. Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

    Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry D. Anderson, Rahul Banerjee, Jesus G. Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E. Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C. Pasquini, Othman S. Akhtar, Surbhi Sidana, Krina K. Patel

    Erschienen: 2026-04-14DOI: 10.1038/s41408-026-01496-w

  9. Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

    Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross S. Firestone, Eric M. Jurgens, Kevin C. Miller, Francesco Maura, Alexander M. Lesokhin, Carlyn R. Tan, Gunjan L. Shah, Neha Korde, Heather J. Landau, Maximillian Merz, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin L. Hultcrantz, Andriy Derkach, David Nemirovsky, Sergio Giralt, Sham Mailankody, Saad Z. Usmani

    Erschienen: 2026-04-12DOI: 10.1038/s41408-026-01494-y

Jahrgänge

2026 · 1382025 · 2272024 · 2242023 · 1942022 · 1732021 · 2032020 · 1262019 · 1022018 · 1282017 · 1422016 · 1352015 · 1102014 · 992013 · 702012 · 502011 · 48

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.